FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Obesity

Belviq (lorcaserin hydrochloride) (by Arena Pharmaceuticals), Approved June 2012
For the chronic management of weight loss

Contrave (naltrexone HCl and bupropion HCl) (by Takeda Pharmaceuticals U.S.A.), Approved September 2014
For chronic weight management

MERIDIA (by Knoll Pharmaceutical), Approved November 1997
Treatment for obesity

Qsymia (phentermine + topiramate extended-release) (by Vivus), Approved July 2012
For the treatment of chronic weight management

Redux (dexfenfluramine hydrochloride) (by Wyeth), Approved May 1996
Treatment for obesity

Saxenda (liraglutide [rDNA origin] injection) (by Novo Nordisk), Approved December 2014
For chronic weight management

Obsessive-Compulsive Disorder

LUVOX (fluvoxamine maleate) (by Solvay Pharmaceuticals, Pharmacia & Upjohn), Approved April 1997
Treatment for obsessive compulsive disorder (OCD) in children and adolescents

Paxil (paroxetine hydrochloride) (by SmithKline Beecham), Approved May 1996
Treatment for panic disorder

Zoloft (sertraline HCl) (by Pfizer), Approved October 1997
Treatment of panic disorder in children ages 6-17

Ocular Hypertension

Alphagan (brimonidine) (by Allergan), Approved September 1996
Treatment for open-angle glaucoma and ocular hypertension

Betaxon (by Alcon), Approved February 2000
For lowering IOP in patients with chronic open-angle glaucoma or ocular hypertension

Cosopt (by Merck), Approved April 1998
Treatment for glaucoma or ocular hypertension

Lumigan (bimatoprost ophthalmic solution) (by Allergan), Approved March 2001
For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Rescula (unoprostone isopropyl ophthalmic solution) 0.15% (by Ciba Vision), Approved August 2000
For the treatment of open-angle glaucoma or ocular hypertension

Travatan (travoprost ophthalmic solution) (by Alcon), Approved March 2001
For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Zioptan (tafluprost ophthalmic solution) (by Merck), Approved February 2012
For the treatment of elevated intraocular pressure

Oral Facial Pain

DentiPatch (lidocaine transoral delivery system) (by Noven Pharmaceuticals), Approved May 1996
Dental anesthetic patch

Osteoarthritis

Bextra (by Pharmacia, Pfizer), Approved November 2001
Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain

Duexis (ibuprofen and famotidine) (by Horizon Pharma), Approved April 2011
For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers

Etodolac (by Royce Laboratories), Approved December 1997
Generic equivalent of Lodine

Etodolac (by Faulding), Approved May 1998
Generic equivalent of Lodine 500 mg tablets

Mobic (meloxicam) Tablets (by Boehringer Ingelheim), Approved April 2000
For relief of the signs and symptoms of osteoarthritis

Naprelan (naproxen sodium) (by Elan Pharmaceuticals, Wyeth), Approved January 1996
Treatment for osteoarthritis and rheumatoid arthritis

Pennsaid (diclofenac sodium topical solution) (by Nuvo Research), Approved November 2009
For the treatment of osteoarthritis of the knee

Supartz (by Smith & Nephew Orthopaedics), Approved January 2001
Joint fluid therapy for treatment of osteoarthritis in the knee

Synvisc, Synvisc-One (Hylan GF 20) (by Genzyme), Approved August 1997
For the treatment of pain associated with osteoarthritis of the knee

Vivlodex (meloxicam) (by Iroko Pharmaceuticals), Approved October 2015
For the management of osteoarthritis pain

Osteoporosis

Activella (Estradiol/Norethindrone Acetate) Tablets (by Novo Nordisk), Approved April 2000
Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause

Alora (by Watson Pharmaceuticals), Approved April 2002
Transdermal patch for the prevention of postmenopausal osteoporosis and treatment of vasomotor menopausal symptoms

Boniva (ibandronate) (by Roche / GlaxoSmithKline), Approved May, 2003 -- UPDATED: NEW FORMULATION APPROVED MARCH, 2005
For the treatment and prevention of osteoporosis

Duavee (conjugated estrogens/bazedoxifene) (by Pfizer), Approved October 2013
For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis

Estradiol tablets (by Barr Laboratories), Approved October 1997
Generic equivalent of Estrace

Estratab (.3 mg ) (by Solvay Pharmaceuticals), Approved March 1998
Treatment for the prevention of osteoporosis

Evista (raloxifene hydrochloride) (by Eli Lilly), Approved December 1997
Treatment for the prevention of osteoporosis

Evista (raloxifene hydrochloride) (by Eli Lilly), Approved September 1999
Osteoporosis treatment

Evista (raloxifene hydrochloride) (by Eli Lilly), Approved September 2007
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women

Femhrt Tablets (by Parke-Davis), October 15, 1999
Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg)

Forteo (teriparatide) (by Eli Lilly), December 2002
For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture.

Fosamax (alendronate sodium) (by Merck), Approved on September 29, 1995
Treatment for osteoporosis in women after menopause and Paget's Disease of Bone

Miacalcin (calcitonin-salmon) Nasal Spray (by Sandoz Pharmaceuticals), Approved on August 17, 1995
Treatment for post-menopausal osteoporosis

Ortho-Prefest (by Ortho-McNeil Pharmaceutical, RW Johnson), October 22, 1999
17 beta estradiol/17 beta estradiol norgestimate tablets

Premarin (conjugated estrogens) (by Wyeth), Approved July of 2003
For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms

Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets) (by Wyeth), Approved November 1995
Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis

Prolia (denosumab) (by Amgen), Approved June 2010
For the treatment of postmenopausal women with osteoporosis at high risk for fracture

Reclast (zoledronic acid) (by Novartis), Approved August 2007
For the treatment of postmenopausal osteoporosis

Vivelle (estradiol transdermal system) (by Novartis), Approved August 2000
For the prevention of postmenopausal osteoporosis

Otitis (Pediatric)

Otiprio (ciprofloxacin otic suspension) (by Otonomy), Approved December 2015
For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement

Otitis Externa (Swimmer's Ear)

Xtoro (finafloxacin otic suspension) 0.3% (by Alcon), Approved December 2014
For the treatment of acute otitis externa

Otitis Media

Floxin otic (by Daiichi Sankyo), Approved December 1997
Treatment for otitis media

Otiprio (ciprofloxacin otic suspension) (by Otonomy), Approved December 2015
For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement

Rocephin (by Roche), Approved January 1998
Treatment for pediatric otitis media

Ovarian Cancer

Ethyol (amifostine) (by Alza), Approved December 8, 1995
Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer

Hycamtin (topotecan hydrochloride) (by SmithKline Beecham), Approved May 1996
Treatment for metastatic ovarian cancer

Lynparza (olaparib) (by AstraZeneca), Approved December 2014
For the treatment of previously treated BRCA mutated advanced ovarian cancer

Rubraca (rucaparib) (by Clovis Oncology), Approved December 2016
For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation

Zejula (niraparib) (by Tesaro), Approved March 2017
For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer